Head-to-head evidence
Loxapine (Adasuve) vs Paliperidone (Invega)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Paliperidone (Invega)
Marketed by Johnson & Johnson
NCT00077714 · Phase 3 · completed
The study was randomized and double-blind, but it enrolled only 12 participants and the registry does not clearly identify a comparator arm. Its primary endpoint was a clinical symptom measure (PANSS), but whether it was met cannot be determined because results are not posted.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Paliperidone (Invega)'s landscape